Heartseed Inc., the company behind Heartseed, explained its cardiac regenerative medicine business and growth strategy in an IR interview, disclosing the status of funding, including its partnership with Novo Nordisk and its IPO, as well as its future clinical trial plans and outlook for commercialization.
Heartseed Inc. discussed its changes in business strategy and future growth direction in an IR interview as it works to bring cardiac regenerative medicine using cardiomyocytes into clinical practice. The interview highlighted its focus on developing cardiac replacement therapy for heart failure and partnering with overseas companies. Its pipeline aimed at commercialization consists of 3 programs, HS-001, HS-005 and HS-040. The first, HS-001, is designed to transplant cardiac spheroids through open-chest surgery.
The company said its global partnership with Novo Nordisk was established under an agreement including an upfront investment and milestone payments, providing a stable source of clinical trial funding and a path to global expansion. The partnership was supported by Novo's sales channels, cell-culture expertise and the potential for expansion of the cardiac replacement therapy market.
Regarding its listing, the company said it conducted an IPO to diversify its sources of funding and had established a structure for continuing clinical trials using a combination of Novo's milestone payments and IPO proceeds. Enrollment in the latter half of the HS-001 trial was becoming stable, with all 10 patients expected to be enrolled by the end of 2024, and commercialization anticipated around 2027.